UBS Group
LBRX

UBS Group’s LB Pharmaceuticals LBRX Stock Holding History

UBS Group’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Sell
85,951
-51,981
-38% -$1.53M ﹤0.01% 4779
2026
Q1 		$3.4M Buy
137,932
+87,219
+172% +$2.01M ﹤0.01% 4463
2025
Q4 		$1.13M Buy
50,713
+49,658
+4,707% +$867K ﹤0.01% 5462
2025
Q3 		$16.7K Buy
+1,055
New +$16.7K ﹤0.01% 8276

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

UBS Group's LBRX Position: Q2 2026 in Review

UBS Group reduced its LB Pharmaceuticals (LBRX) stake by 38% in Q2 2026, selling an estimated $1.53M and leaving 85,951 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #4779.

UBS Group first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.4M in Q1 2026. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • UBS Group held 85,951 shares of LB Pharmaceuticals worth $2.79M as of Q2 2026.
  • UBS Group sold 51,981 LB Pharmaceuticals shares in Q2 2026, an estimated $1.53M.
  • LB Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4779 holding.
  • UBS Group first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • UBS Group's LB Pharmaceuticals position peaked at $3.4M in Q1 2026.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.